Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23474997 | 1.00 | GAA (0.38) | GAAHRH3MAOBSLC6A4MEN1 | |
| SCHEMBL23474916 | 1.00 | GAA (0.38) | GAAHRH3MAOBSLC6A4MEN1 | |
| SCHEMBL23474963 | 0.89 | ALDH1A1 (0.33) | GAAHRH3MAOBSLC6A4TSHR | |
| SCHEMBL23474913 | 0.82 | HRH3 (0.47) | HRH3MAOBMEN1KMT2ASIGMAR1 | |
| SCHEMBL23474957 | 0.82 | HRH3 (0.47) | HRH3MAOBMEN1KMT2ASIGMAR1 | |
| SCHEMBL23475002 | 0.82 | HRH3 (0.47) | HRH3MAOBMEN1KMT2ASIGMAR1 | |
| SCHEMBL23474891 | 0.81 | SIGMAR1 (0.37) | HRH3MAOBSIGMAR1 | |
| SCHEMBL23474806 | 0.81 | SIGMAR1 (0.37) | HRH3MAOBSIGMAR1 | |
| SCHEMBL23474848 | 0.81 | SIGMAR1 (0.37) | HRH3MAOBSIGMAR1 | |
| SCHEMBL23474915 | 0.80 | HRH3 (0.38) | HRH3MAOBMEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171554-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171554-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS | CDK6, ESR1, CDK4 | GAA 3365/4885HRH3 2518/4885MAOB 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.